Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions).

Rageth, Christoph J; O'Flynn, Elizabeth A M; Pinker, Katja; Kubik-Huch, Rahel A; Mundinger, Alexander; Decker, Thomas; Tausch, Christoph; Dammann, Florian; Baltzer, Pascal A; Fallenberg, Eva Maria; Foschini, Maria P; Dellas, Sophie; Knauer, Michael; Malhaire, Caroline; Sonnenschein, Martin; Boos, Andreas; Morris, Elisabeth; Varga, Zsuzsanna (2019). Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast cancer research and treatment, 174(2), pp. 279-296. Springer 10.1007/s10549-018-05071-1

Preview

Text Rageth2019_Article_SecondInternationalConsensusCo.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (722kB) | Preview

PURPOSE

The second International Consensus Conference on B3 lesions was held in Zurich, Switzerland, in March 2018, organized by the International Breast Ultrasound School to re-evaluate the consensus recommendations.

METHODS

This study (1) evaluated how management recommendations of the first Zurich Consensus Conference of 2016 on B3 lesions had influenced daily practice and (2) reviewed current literature towards recommendations to biopsy.

RESULTS

In 2018, the consensus recommendations for management of B3 lesions remained almost unchanged: For flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL) and radial scars (RS) diagnosed on core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB), excision by VAB in preference to open surgery, and for atypical ductal hyperplasia (ADH) and phyllodes tumors (PT) diagnosed at VAB or CNB, first-line open surgical excision (OE) with follow-up surveillance imaging for 5 years. Analyzing the Database of the Swiss Minimally Invasive Breast Biopsies (MIBB) with more than 30,000 procedures recorded, there was a significant increase in recommending more frequent surveillance of LN [65% in 2018 vs. 51% in 2016 (p = 0.004)], FEA (72% in 2018 vs. 62% in 2016 (p = 0.005)), and PL [(76% in 2018 vs. 70% in 2016 (p = 0.04)] diagnosed on VAB. A trend to more frequent surveillance was also noted also for RS [77% in 2018 vs. 67% in 2016 (p = 0.07)].

CONCLUSIONS

Minimally invasive management of B3 lesions (except ADH and PT) with VAB continues to be appropriate as an alternative to first-line OE in most cases, but with more frequent surveillance, especially for LN.

Interest & Impact

Downloads

171 since deposited on 13 Dec 2018
18 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item